期刊
CURRENT PROBLEMS IN CANCER
卷 41, 期 1, 页码 37-47出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.currproblcancer.2016.11.002
关键词
Endometrial cancer; Fibroblast growth factor; Angiogenesis
类别
资金
- Novartis Pharmaceuticals Corporation
Novel treatments that improve outcomes for patients with recurrent or metastatic endometrial cancer (EC) remain an unmet need. Aberrant signaling by fibroblast growth factors (FGFs) and FGF receptors (FGFRs) has been implicated in several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical development for the treatment of EC. (C) 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据